A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Insulin analogues have been engineered to enhance desired molecular properties without altering immunogenicity. The majority of insulin pharmacology studies are conducted in healthy volunteers and patients with type 1 diabetes. At present, there are more patients with type 2 than type 1 diabetes receiving insulin treatment. As the responsibility for initiating insulin therapy in these patients continues to shift to primary care, it will be important for general practitioners to understand the different pharmacological properties of insulin preparations in patients with type 2 diabetes, so that treatment can be adapted to meet patients' physiological and lifestyle requirements. The purpose of this review is to summarize pharmacological studies of insulin analogues in patients with type 2 diabetes. Faster onset of action of rapid acting insulin analogues has improved postprandial glycaemic control. Biphasic insulin analogues are associated with a lower incidence of nocturnal hypoglycaemia compared with human biphasic preparations and allow for intensification from once to twice or thrice daily dosing. More predictable glycaemic‐lowering profiles of the insulin analogues have also led to reductions in nocturnal hypoglycaemia, particularly comparing long‐acting insulin analogues with protaminated human insulin. Enhancing insulin self‐association and reversible binding with albumin has led to further reductions in variability. However, improvements can still be made. Effective once daily clinical dosing of long‐acting insulin analogues is not possible in all patients. In addition, the protaminated component of biphasic insulin analogues do not provide the duration of action or profile for physiological basal insulin replacement and neither insulin glargine nor insulin detemir are suitable for mixing with other insulin analogues as this would substantially alter their pharmacokinetic properties. Enhancing the pharmacological predictability and extending the duration of action could simplify insulin titration and further reduce the incidence of hypoglycaemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
Insulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059 · cited 1×
“The type 1 IGF receptor binding has been linked to tumour development in rodents [22] and these findings have led to the discontinuation of specific insulin analogues.”
BackgroundThe influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · cited 1×
“[31] also reported an association between the use of any insulin and cancer risk relative to patients receiving oral antidiabetic drug treatment, with no additional attributable risk of insulin glargine over other (predominantly human) insulin preparations.”
BackgroundKurtzhals, P., Schäffer, L., Sørensen, A., Kristensen, C., Jonassen, I., Schmid, C., & Trüb, T. (2000) · Diabetes · doi:10.2337/diabetes.49.6.999 · Cited by 739 · cited 2×
“Currently available insulin analogues exhibit an affinity for the type 1 IGF receptor ranging between 16 and 641% relative to native human insulin, depending on the specific insulin analogue and cell line studied [23,24,57].”
BackgroundHemkens, L. G., Grouven, U., Bender, R., Günster, C., Gutschmidt, S., Selke, G. W., & Sawicki, P. T. (2009) · Diabetologia · doi:10.1007/s00125-009-1418-4 · Cited by 607 · cited 1×
“The largest study of 127 031 patients reported an increase in the risk of cancer with higher doses and longer duration of exposure to any insulin and that after adjusting for insulin dose, insulin glargine-treated patients were at highest risk [26].”
BackgroundRyysy, L., Häkkinen, A. M., Goto, T., Vehkavaara, S., Westerbacka, J., Halavaara, J., & Yki-Järvinen, H. (2000) · Diabetes · doi:10.2337/diabetes.49.5.749 · Cited by 431 · cited 1×
“[10] found that increases in total body adiposity rather than subcutaneous thickness were most closely associated with insulin dose and delayed insulin absorption.”
BackgroundJonasson, J. M., Ljung, R., Talbäck, M., Haglund, B., Gudbjörnsdòttir, S., & Steineck, G. (2009) · Diabetologia · doi:10.1007/s00125-009-1444-2 · Cited by 412
Klein, O., Lynge, J., Endahl, L., Damholt, B., Nosek, L., & Heise, T. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00685.x · Cited by 251
Rosenstock, J., Fonseca, V., McGill, J. B., Riddle, M., Hallé, J. P., Hramiak, I., Johnston, P., & Davis, M. (2009) · Diabetologia · doi:10.1007/s00125-009-1452-2 · Cited by 141 · cited 1×
“No evidence for increased cancer risk has been reported during an extended trial investigating the effects of neutral protamine Hagedorn (NPH) insulin and insulin glargine effects on the development of retinopathy [29] or in the meta-analysis of 31 insulin glargine studies [30].”
Background
Cited by
Obesity and diabetes: the increased risk of cancer and cancer-related mortality
Gallagher, E. J., & LeRoith, D. (2015) · Physiological Reviews · doi:10.1152/physrev.00030.2014 · Cited by 806
“A number of insulin analogs were developed to create a more physiological meal-related insulin profile and to reduce hypoglycemia (48, 95).”
BackgroundPI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis
Schultze, S. M., Hemmings, B. A., Niessen, M., & Tschopp, O. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411002109 · Cited by 540
A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
Haahr, H., & Heise, T. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0165-y · Cited by 226
Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region
Nosek, L., Coester, H.-V., Roepstorff, C., Thomsen, H. F., Kristensen, N. R., Haahr, H., & Heise, T. (2014) · Clinical Drug Investigation · doi:10.1007/s40261-014-0218-x · Cited by 42
Kumar, A., Franek, E., Wise, J., Niemeyer, M., Mersebach, H., & Simó, R. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163350 · Cited by 38
Metadata
- Authors
- Evans, M., Schumm‐Draeger, P. M., Vora, J., & King, A. B.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2011-06-21
- Volume
- 13
- Issue
- 8
- Pages
- 677-684
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2053830590
- Cited by
- 146
- References
- 9
- FWCI
- 9.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01395.x
- The paper
- Evans, M., Schumm‐Draeger, P. M., Vora, J., & King, A. B. (2011). A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01395.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.